Charles River Laboratories Long-Term Investments 2010-2024 | CRL

Charles River Laboratories long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • Charles River Laboratories long-term investments for the quarter ending September 30, 2024 were $0.236B, a 21.82% decline year-over-year.
  • Charles River Laboratories long-term investments for 2023 were $0.244B, a 21.76% decline from 2022.
  • Charles River Laboratories long-term investments for 2022 were $0.312B, a 54.75% increase from 2021.
  • Charles River Laboratories long-term investments for 2021 were $0.201B, a INF% increase from 2020.
Charles River Laboratories Annual Long-Term Investments
(Millions of US $)
2023 $244
2022 $312
2021 $201
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Charles River Laboratories Quarterly Long-Term Investments
(Millions of US $)
2024-09-30 $236
2024-06-30 $232
2024-03-31 $244
2023-12-31 $244
2023-09-30 $302
2023-06-30 $300
2023-03-31 $294
2022-12-31 $312
2022-09-30
2022-06-30
2022-03-31
2021-12-31 $201
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Services $9.516B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $91.424B 11.34
Cencora (COR) United States $47.484B 17.51
DiDi Global (DIDIY) China $23.330B 0.00
Natera (NTRA) United States $21.401B 0.00
ICON (ICLR) Ireland $16.136B 14.37
Viatris (VTRS) United States $15.576B 4.80
Avantor (AVTR) United States $13.422B 20.12
Revvity (RVTY) United States $13.376B 23.24
CochLear (CHEOY) Australia $12.844B 0.00
BioMerieux (BMXMF) France $12.666B 0.00
Solventum (SOLV) United States $11.583B 0.00
Medpace Holdings (MEDP) United States $9.789B 27.58
Doximity (DOCS) United States $9.620B 56.63
HealthEquity (HQY) United States $8.966B 48.66
Sonic Healthcare (SKHHY) Australia $8.758B 0.00
Bausch + Lomb (BLCO) Canada $6.885B 32.05
Life Times (LTH) United States $5.085B 33.66
Sotera Health (SHC) United States $3.855B 20.62
Organon (OGN) United States $3.757B 3.79
BrightSpring Health Services (BTSG) United States $3.247B 69.07
Surgery Partners (SGRY) United States $2.892B 32.97
PACS (PACS) United States $2.606B 0.00
Concentras Parent (CON) United States $2.581B 0.00
Ardent Health Partners (ARDT) United States $2.375B 0.00
Premier (PINC) United States $2.143B 11.15
Alignment Healthcare (ALHC) United States $2.126B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $1.952B 0.00
GoodRx Holdings (GDRX) United States $1.616B 42.40
Teladoc Health (TDOC) United States $1.537B 0.00
Pediatrix Medical (MD) United States $1.255B 12.28
CareDx (CDNA) United States $1.183B 0.00
Progyny (PGNY) United States $1.164B 23.57
Establishment Labs Holdings (ESTA) $1.050B 0.00
AMN Healthcare Services Inc (AMN) United States $0.954B 6.46
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Embecta (EMBC) United States $0.778B 5.18
SBC Medicals (SBC) United States $0.677B 0.00
Agilon Health (AGL) United States $0.655B 0.00
InnovAge Holding (INNV) United States $0.647B 0.00
Auna S.A (AUNA) Luxembourg $0.536B 0.00
Sonida Senior Living (SNDA) United States $0.425B 0.00
DocGo (DCGO) United States $0.410B 15.46
Enhabit (EHAB) United States $0.366B 31.61
COMPASS Pathways (CMPS) United Kingdom $0.326B 0.00
LifeMD (LFMD) United States $0.241B 0.00
ModivCare (MODV) United States $0.223B 12.09
Sera Prognostics (SERA) United States $0.209B 0.00
Beauty Health (SKIN) United States $0.200B 0.00
Biodesix (BDSX) United States $0.180B 0.00
Nutex Health (NUTX) United States $0.156B 0.00
Ascend Wellness Holdings (AAWH) United States $0.100B 0.00
So-Young (SY) China $0.092B 22.25
MultiPlan (MPLN) United States $0.084B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.043B 0.00
NeueHealth (NEUE) United States $0.041B 1.08
Co-Diagnostics (CODX) United States $0.034B 0.00
Pheton Holdings (PTHL) China $0.030B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.020B 0.00
Oncology Institute (TOI) United States $0.014B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00